NY-ESO-1: review of an immunogenic tumor antigen. Review uri icon

Overview

abstract

  • In the 9 years since its discovery, cancer-testis antigen NY-ESO-1 has made one of the fastest transitions from molecular, cellular, and immunological description to vaccine and immunotherapy candidate, already tested in various formulations in more than 30 clinical trials worldwide. Its main characteristic resides in its capacity to elicit spontaneous antibody and T-cell responses in a proportion of cancer patients. An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here.

publication date

  • January 1, 2006

Research

keywords

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Gene Expression Regulation, Neoplastic
  • Membrane Proteins
  • Neoplasms

Identity

Scopus Document Identifier

  • 33746211234

Digital Object Identifier (DOI)

  • 10.1016/S0065-230X(06)95001-5

PubMed ID

  • 16860654

Additional Document Info

volume

  • 95